This excerpt taken from the ABII 8-K filed Nov 8, 2007.
The following is a summary of some of the information contained elsewhere in this information statement. It is included for convenience only and should not be considered complete. This summary is qualified in its entirety by the more detailed information set forth elsewhere in this information statement, including our financial statements and notes thereto. We urge you to read carefully the entire information statement, especially the risks discussed under Risk Factors and our financial statements.
Unless the context otherwise requires, references in this information statement to New Abraxis, we, us and our refer to New Abraxis, Inc. and its subsidiaries, including our operating subsidiary Abraxis BioScience, LLC (which we refer to as New Abraxis, LLC in this information statement); references to Old Abraxis refer to Abraxis BioScience, Inc. prior to giving effect to the holding company merger described in this information statement; references to Abraxis BioScience refer to Old Abraxis prior to giving effect to the holding company merger or to APP Pharmaceuticals, Inc. (an entity formerly known as Generico Holdings, Inc. and created by Old Abraxis to effectuate the holding company merger) after the holding company merger and prior to giving effect to the separation and distribution; and references to New APP refer to APP Pharmaceuticals, Inc. and its subsidiaries, including its operating subsidiary APP Pharmaceuticals, LLC (which we refer to as New APP LLC in this information statement), but excluding New Abraxis, after giving effect to the separation and distribution. After giving effect to the separation and distribution, New Abraxis will change its name to Abraxis BioScience, Inc. The transaction in which we will be separated from Abraxis BioScience and become an independent publicly-traded company is sometimes referred to in this information statement as the separation, the distribution or the spin-off.
We describe in this information statement the business to be contributed to us by Abraxis BioScience as if it were our business for all historical periods described. However, we are a newly formed entity that will not conduct any operations prior to the separation and distribution. Following the separation and distribution, we will be an independent public company. Accordingly, our historical financial results as part of Abraxis BioScience contained herein may not reflect our financial results in the future as an independent company or what our financial results would have been had we been a stand-alone company during the periods presented.